Efficacy, reactogenicity, and safety of the adjuvanted recombinant zoster vaccine for the prevention of herpes zoster in Chinese adults ≥ 50 years: A randomized, placebo-controlled trial

References

• Centers for Disease Control and Prevention. Shingles (herpes zoster): clinical overview. 2023 [accessed 2023 Aug 18]. https://www.cdc.gov/shingles/hcp/clinical-overview.html.
   Google Scholar
• Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open. 2014;4(6):e004833. doi:10.1136/bmjopen-2014-004833.
   PubMed Web of Science ®Google Scholar
• Lecrenier N, Beukelaers P, Colindres R, Curran D, De Kesel C, De Saegher JP, Didierlaurent AM, Ledent EY, Mols JF, Mrkvan T, et al. Development of adjuvanted recombinant zoster vaccine and its implications for shingles prevention. Expert Rev Vaccines. 2018;17(7):619–10. doi:10.1080/14760584.2018.1495565.
   PubMed Web of Science ®Google Scholar
• Leroux-Roels I, Leroux-Roels G, Clement F, Vandepapeliere P, Vassilev V, Ledent E, Heineman TC. A phase 1/2 clinical trial evaluating safety and immunogenicity of a varicella zoster glycoprotein E subunit vaccine candidate in young and older adults. J Infect Dis. 2012;206(8):1280–90. doi:10.1093/infdis/jis497.
   PubMed Web of Science ®Google Scholar
• Chlibek R, Bayas JM, Collins H, de la Pinta ML, Ledent E, Mols JF, Heineman TC. Safety and immunogenicity of an AS01-adjuvanted varicella-zoster virus subunit candidate vaccine against herpes zoster in adults ≥ 50 years of age. J Infect Dis. 2013;208(12):1953–61. doi:10.1093/infdis/jit365.
   PubMed Web of Science ®Google Scholar
• Chlibek R, Smetana J, Pauksens K, Rombo L, Van den Hoek JA, Richardus JH, Plassmann G, Schwarz TF, Ledent E, Heineman TC. Safety and immunogenicity of three different formulations of an adjuvanted varicella-zoster virus subunit candidate vaccine in older adults: a phase II, randomized, controlled study. Vaccine. 2014;32(15):1745–53. doi:10.1016/j.vaccine.2014.01.019.
   PubMed Web of Science ®Google Scholar
• Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang SJ, Levin MJ, McElhaney JE, Poder A, Puig-Barberà J, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015;372(22):2087–96. doi:10.1056/NEJMoa1501184.
   PubMed Web of Science ®Google Scholar
• Cunningham AL, Lal H, Kovac M, Chlibek R, Hwang SJ, Díez-Domingo J, Godeaux O, Levin MJ, McElhaney JE, Puig-Barberà J, et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med. 2016;375(11):1019–32. doi:10.1056/NEJMoa1603800.
   PubMed Web of Science ®Google Scholar
• López-Fauqued M, Campora L, Delannois F, El Idrissi M, Oostvogels L, De Looze FJ, Diez-Domingo J, Heineman TC, Lal H, McElhaney JE, et al. Safety profile of the adjuvanted recombinant zoster vaccine: pooled analysis of two large randomised phase 3 trials. Vaccine. 2019;37(18):2482–93. doi:10.1016/j.vaccine.2019.03.043.
   PubMed Web of Science ®Google Scholar
• Kim JH, Diaz-Decaro J, Jiang N, Hwang SJ, Choo EJ, Co M, Hastie A, Hui DSC, Irimajiri J, Lee J, et al. The adjuvanted recombinant zoster vaccine is efficacious and safe in Asian adults ≥ 50 years of age: a sub-cohort analysis of the ZOE-50 and ZOE-70 randomized trials. Hum Vaccin Immunother. 2021;17(7):2050–7. doi:10.1080/21645515.2020.1859321.
   PubMed Web of Science ®Google Scholar
• Willer DO, Oostvogels L, Cunningham AL, Gervais P, Gorfinkel I, Hyung Kim J, Talarico C, Wascotte V, Zahaf T, Colindres R, et al. Efficacy of the adjuvanted recombinant zoster vaccine (RZV) by sex, geographic region, and geographic ancestry/ethnicity: a post-hoc analysis of the ZOE-50 and ZOE-70 randomized trials. Vaccine. 2019;37(43):6262–7. doi:10.1016/j.vaccine.2019.09.028.
   PubMed Web of Science ®Google Scholar
• Sun Y, Jackson K, Dalmon CA, Shapiro BL, Nie S, Wong C, Arnold BF, Porco TC, Acharya NR. Effectiveness of the recombinant zoster vaccine among Kaiser permanente Hawaii enrollees aged 50 and older: a retrospective cohort study. Vaccine. 2021;39(29):3974–82. doi:10.1016/j.vaccine.2021.05.056.
   PubMed Web of Science ®Google Scholar
• Sun Y, Kim E, Kong CL, Arnold BF, Porco TC, Acharya NR. Effectiveness of the recombinant zoster vaccine in adults aged 50 and older in the United States: a claims-based cohort study. Clin Infect Dis. 2021;73(6):949–56. doi:10.1093/cid/ciab121.
   PubMed Web of Science ®Google Scholar
• Izurieta HS, Wu X, Forshee R, Lu Y, Sung H-M, Agger PE, Chillarige Y, Link-Gelles R, Lufkin B, Wernecke M, et al. Recombinant zoster vaccine (shingrix): real-world effectiveness in the first 2 years post-licensure. Clin Infect Dis. 2021;73(6):941–8. doi:10.1093/cid/ciab125.
   PubMed Web of Science ®Google Scholar
• Parikh R, Singer D, Chmielewski-Yee E, Dessart C. Effectiveness and safety of recombinant zoster vaccine: a review of real-world evidence. Hum Vaccin Immunother. 2023;19(3):2263979. doi:10.1080/21645515.2023.2263979.
   PubMed Web of Science ®Google Scholar
• Parikh R, Widenmaier R, Lecrenier N. A practitioner’s guide to the recombinant zoster vaccine: review of national vaccination recommendations. Expert Rev Vaccines. 2021;20(9):1065–75. doi:10.1080/14760584.2021.1956906.
   PubMed Web of Science ®Google Scholar
• GSK. GSK announces approval of shingrix in China for prevention of shingles in adults aged 50 and over. 2019 [accessed 2023 Aug 17]. https://www.gsk.com/en-gb/media/press-releases/gsk-announces-approval-of-shingrix-in-china-for-prevention-of-shingles-in-adults-aged-50-and-over/.
   Google Scholar
• Lee C, Jiang N, Tang H, Ye C, Yuan Y, Curran D. Potential public health impact of the adjuvanted recombinant zoster vaccine among people aged 50 years and older in Beijing. Hum Vaccin Immunother. 2021;17(10):3735–46. doi:10.1080/21645515.2021.1932216.
   PubMed Web of Science ®Google Scholar
• Yin D, Van Oorschot D, Jiang N, Marijam A, Saha D, Wu Z, Tang H, Diaz-Decaro J, Watson P, Xie X, et al. A systematic literature review to assess the burden of herpes zoster disease in China. Expert Rev Anti Infect Ther. 2021;19(2):165–79. doi:10.1080/14787210.2020.1792290.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration, U.S. Department of Health and Human Services, Center for Biologics Evaluation and Research. Guidance for industry: toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials. 2007 [accessed 2023 Aug 17]. https://www.fda.gov/media/73679/download.
   Google Scholar
• Boutry C, Hastie A, Diez-Domingo J, Tinoco JC, Yu CJ, Andrews C, Beytout J, Caso C, Cheng HS, Cheong HJ, et al. The adjuvanted recombinant zoster vaccine confers long-term protection against herpes zoster: interim results of an extension study of the pivotal phase 3 clinical trials ZOE-50 and ZOE-70. Clin Infect Dis. 2022;74(8):1459–67. doi:10.1093/cid/ciab629.
   PubMed Web of Science ®Google Scholar
• Tan X, Zhang Y, Shao H. Healthy China 2030, a breakthrough for improving health. Glob Health Promot. 2019;26(4):96–9. doi:10.1177/1757975917743533.
   PubMed Web of Science ®Google Scholar
• Wang G, Yao Y, Wang Y, Gong J, Meng Q, Wang H, Wang W, Chen X, Zhao Y. Determinants of COVID-19 vaccination status and hesitancy among older adults in China. Nat Med. 2023;29(3):623–31. doi:10.1038/s41591-023-02241-7.
   PubMed Web of Science ®Google Scholar